Report Adverse Event or Product Quality Complaint   US Site   Global Site             

Header Logo
  • Prescribing Information
  • Therapy areas
    • All Therapeutic Areas
    • Cardiovascular, Renal and Metabolism
    • Immunology
    • Infection
    • Oncology
    • Rare Disease (Alexion)
    • Respiratory
  • Disease Education
  • Resources
    • Congress Library
    • Clinical Trials
    • Continuing Education
    • Patient Support
    • Pipeline
  • Connect
    • Connect with an MSL
    • Connect with an MSL
    • Submit an MIR
    • Give Feedback

Search Medical Information

Login

Request a field medical follow-up

  • Home
  • Congress Library
  • ERS 2025

European Respiratory Society (ERS) – 35th Annual Congress

September 27 - October 1, 2025

  1. All
  2. FASENRA (benralizumab)
  3. Respiratory Unbranded
  4. TEZSPIRE (tezepelumab)
  5. BREZTRI/TRIXEO
  6. NOVELTY
  7. Tozorakimab

PDF

Changes in airway structure/function with benralizumab treatment of severe eosinophilic asthma (SEA) observed with Functional Respiratory Imaging (FRI)

PDF

Predicting long-term remission with benralizumab in severe eosinophilic asthma (SEA): Post-hoc analysis of SIROCCO, CALIMA, BORA

PDF

Asthma control and clinical remission in severe eosinophilic asthma (SEA) after 2 years of benralizumab treatment: prospective real-world data from XALOC-2

PDF

Effects of benralizumab on serum biomarkers and biomarker response after shifting from mepolizumab to benralizumab in eosinophilic granulomatosis with polyangiitis (EGPA)

PDF

Whole blood transcriptomic profile effects of benralizumab or mepolizumab in eosinophilic granulomatosis with polyangiitis

PDF

Asthma remission in patients with eosinophilic granulomatosis with polyangiitis (EGPA) following 2 years of treatment with anti-IL-5/R therapies

PDF

EGPA disease burden in Europe and US: evidence from real-world clinical practice

PDF

Healthcare resource utilization (HCRU) and costs in patients with eosinophilic granulomatosis with polyangiitis (EGPA): a retrospective observational cohort study in England

PDF

Airway IL-33 levels are similar in current and former smokers with stable or exacerbating COPD

PDF

Predictors of recovery in US patients hospitalized for viral lower respiratory tract disease: an analysis of linked electronic health records and claims data

PDF

Real-world study on causes of death in people with Chronic Obstructive Pulmonary Disease (COPD) in England

PDF

Risk factors for mortality and IMV/ECMO in US patients hospitalized for viral LRTD

PDF

Real-world occurrence of cardiopulmonary events among patients with COPD: the ABACOS-OUTCOMES Study (US)

PDF

Early and continued improvements in asthma control in patients with severe, uncontrolled asthma after tezepelumab initiation: real-world ASCENT study

PDF

Bronchoscopy measurements of tezepelumab pharmacokinetics and TSLP in asthmatic patients

PDF

OCS reduction with tezepelumab in OCS-dependent patients with severe allergic, eosinophilic asthma in WAYFINDER

PDF

On-treatment clinical remission with tezepelumab in OCS-dependent patients with severe asthma in WAYFINDER

PDF

Efficacy of tezepelumab in adults with severe, uncontrolled chronic rhinosinusitis with nasal polyps and comorbid NSAID-exacerbated respiratory disease (WAYPOINT)

PDF

Tezepelumab reduces inflammatory biomarkers in adults with severe chronic rhinosinusitis with nasal polyps with and without comorbid asthma: results from the phase 3 WAYPOINT study

PDF

Utility of CompEx as a component of clinical remission in NAVIGATOR

PDF

Reduced mortality and cardiopulmonary risk for patients with COPD and asthma when initiating single inhaler triple therapy compared to multiple inhaler triple therapy (MITT): MAZI Asthma Study

PDF

Burden, characteristics and outcomes of COPD patients experiencing moderate or severe exacerbations on triple therapy (ANTLIA NOVELTY)

PDF

Tozorakimab exerts unique dual pharmacology to reduce COPD epithelial remodelling [poster]

PDF

Tozorakimab exerts unique dual pharmacology to reduce COPD epithelial remodelling [Oral presentation]

PDF

Changes in airway structure/function with benralizumab treatment of severe eosinophilic asthma (SEA) observed with Functional Respiratory Imaging (FRI)

PDF

Predicting long-term remission with benralizumab in severe eosinophilic asthma (SEA): Post-hoc analysis of SIROCCO, CALIMA, BORA

PDF

Asthma control and clinical remission in severe eosinophilic asthma (SEA) after 2 years of benralizumab treatment: prospective real-world data from XALOC-2

PDF

Effects of benralizumab on serum biomarkers and biomarker response after shifting from mepolizumab to benralizumab in eosinophilic granulomatosis with polyangiitis (EGPA)

PDF

Whole blood transcriptomic profile effects of benralizumab or mepolizumab in eosinophilic granulomatosis with polyangiitis

PDF

Asthma remission in patients with eosinophilic granulomatosis with polyangiitis (EGPA) following 2 years of treatment with anti-IL-5/R therapies

PDF

EGPA disease burden in Europe and US: evidence from real-world clinical practice

PDF

Healthcare resource utilization (HCRU) and costs in patients with eosinophilic granulomatosis with polyangiitis (EGPA): a retrospective observational cohort study in England

PDF

Airway IL-33 levels are similar in current and former smokers with stable or exacerbating COPD

PDF

Predictors of recovery in US patients hospitalized for viral lower respiratory tract disease: an analysis of linked electronic health records and claims data

PDF

Real-world study on causes of death in people with Chronic Obstructive Pulmonary Disease (COPD) in England

PDF

Risk factors for mortality and IMV/ECMO in US patients hospitalized for viral LRTD

PDF

Real-world occurrence of cardiopulmonary events among patients with COPD: the ABACOS-OUTCOMES Study (US)

PDF

Early and continued improvements in asthma control in patients with severe, uncontrolled asthma after tezepelumab initiation: real-world ASCENT study

PDF

Bronchoscopy measurements of tezepelumab pharmacokinetics and TSLP in asthmatic patients

PDF

OCS reduction with tezepelumab in OCS-dependent patients with severe allergic, eosinophilic asthma in WAYFINDER

PDF

On-treatment clinical remission with tezepelumab in OCS-dependent patients with severe asthma in WAYFINDER

PDF

Efficacy of tezepelumab in adults with severe, uncontrolled chronic rhinosinusitis with nasal polyps and comorbid NSAID-exacerbated respiratory disease (WAYPOINT)

PDF

Tezepelumab reduces inflammatory biomarkers in adults with severe chronic rhinosinusitis with nasal polyps with and without comorbid asthma: results from the phase 3 WAYPOINT study

PDF

Utility of CompEx as a component of clinical remission in NAVIGATOR

PDF

Reduced mortality and cardiopulmonary risk for patients with COPD and asthma when initiating single inhaler triple therapy compared to multiple inhaler triple therapy (MITT): MAZI Asthma Study

PDF

Burden, characteristics and outcomes of COPD patients experiencing moderate or severe exacerbations on triple therapy (ANTLIA NOVELTY)

PDF

Tozorakimab exerts unique dual pharmacology to reduce COPD epithelial remodelling [poster]

PDF

Tozorakimab exerts unique dual pharmacology to reduce COPD epithelial remodelling [Oral presentation]

Disclaimer

Some content may have changed since publication. Some links may require registration/login to access the content. Any attached publications and/or any tables or figures derived from the publications are copyright-protected works. AstraZeneca has obtained permission from the copyright owner to use this work on this site. You may not reproduce, prepare derivative works from, display or distribute this work unless you obtain the permission of the copyright owner, or as otherwise might be permitted by law.

Connessiallasalute.it

This site is intended for healthcare professionals practicing in the US.
©2026 AstraZeneca. All rights reserved.

US-107328
Last Updated 3/26

Contact Us

About Us

AstraZeneca-US.com

Grant Opportunities  

Survey Feedback

Your Privacy Choice

Consumer Health Data 
Privacy Notice

Privacy Notice | Legal Notice | Cookie Preferences

Welcome to AstraZeneca Medical Information

The information provided on this site is intended for use by healthcare professionals practicing in the US. The dissemination of this information may be subject to different medical and regulatory requirements in other countries.

 

This web site is intended to help healthcare professionals practicing in the US and AstraZeneca authorized persons find scientifically balanced, evidence-based information about AstraZeneca drugs, submit a question, ask for field medical follow-up, and explore links to professional and patient support resources.

 

Are you a healthcare professional practicing in the United States?

I am an AstraZeneca authorized person   What is an AstraZeneca authorized person?
This website is only intended for healthcare professionals practicing in the United States and authorized AstraZeneca personnel. AstraZeneca US Headquarters personnel and US Field Medical personnel are authorized to browse and search the database for their own background knowledge and insight. US Field Sales personnel should not access or browse this site. None of the content of this site should be directly linked or distributed without approval.
I am not a healthcare professional practicing in the United States